Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006268 · ClinicalTrials.gov registry record · Phase 1
Immunotoxin Therapy in Treating Patients With Malignant Glioma
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Study locations
NCT00006268 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by New Approaches to Brain Tumor Therapy Consortium. The trial reports 11 study locations across 9 states.
The verdict
NCT00006268, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11
- Study locations
Study Summary
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for malignant glioma. PURPOSE: Phase I/II trial to study the effectiveness of immunotoxin therapy in treating patients who have malignant glioma.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL cintredekin besudotox
- DRUG isolated perfusion
Study Locations (11)
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
- National Institute of Neurological Disorders and Stroke - Bethesda
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
Florida
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Michigan
- Josephine Ford Cancer Center at Henry Ford Health System - Detroit
North Carolina
- Comprehensive Cancer Center at Wake Forest University - Winston-Salem
Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006268
The ClinicalTrials.gov registry entry for NCT00006268 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is New Approaches to Brain Tumor Therapy Consortium, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which conventional surgery is the first listed.
NCT00006268 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Maryland, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT00006268 about?
NCT00006268 is a clinical study titled "Immunotoxin Therapy in Treating Patients With Malignant Glioma". RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for malignant glioma. PURPOSE: Phase I/II trial to study the effectiveness of immunotoxin therapy in treating patients who have malignant glioma.
What is the current status of trial NCT00006268?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-10. Estimated completion is 2005-03.
What conditions does trial NCT00006268 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00006268?
The interventions under investigation include: conventional surgery (PROCEDURE), cintredekin besudotox (BIOLOGICAL), isolated perfusion (DRUG).
Who is sponsoring clinical trial NCT00006268?
This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006268 being conducted?
This trial has 11 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
-
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.